Global Nonalcoholic Steatohepatitis (NASH) Market Research Report 2025(Status and Outlook)

March 2025 | 238 pages | ID: G18E2BC02C71EN
Bosson Research

Abstracts

Report Overview

Non-alcoholic steatohepatitis (NASH), is one of the common liver diseases, often called silent liver disease. The major feature in NASH is fat deposition in the liver, along with inflammation.

This report provides a deep insight into the global Nonalcoholic Steatohepatitis (NASH) market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.

The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Nonalcoholic Steatohepatitis (NASH) Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.

In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Nonalcoholic Steatohepatitis (NASH) market in any manner.

Global Nonalcoholic Steatohepatitis (NASH) Market: Market Segmentation Analysis

The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.

Key Company

AstraZeneca

Arena Pharmaceuticals

GSK

Novo Nordisk

Roche

Vivus

Arisaph Pharmaceuticals

Cempra Pharmaceuticals

Galectin Therapeutics

Galmed Pharmaceuticals

Genfit

Gilead

Market Segmentation (by Type)

Obeticholic acid?OCA?

Selonsertib

Market Segmentation (by Application)

Hospital Pharmacy

Online Provider

Retail Pharmacy

Geographic Segmentation

• North America (USA, Canada, Mexico)
• Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
• Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
• South America (Brazil, Argentina, Columbia, Rest of South America)
• The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Key Benefits of This Market Research:

• Industry drivers, restraints, and opportunities covered in the study
• Neutral perspective on the market performance
• Recent industry trends and developments
• Competitive landscape & strategies of key players
• Potential & niche segments and regions exhibiting promising growth covered
• Historical, current, and projected market size, in terms of value
• In-depth analysis of the Nonalcoholic Steatohepatitis (NASH) Market
• Overview of the regional outlook of the Nonalcoholic Steatohepatitis (NASH) Market:

Key Reasons to Buy this Report:

• Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
• This enables you to anticipate market changes to remain ahead of your competitors
• You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
• The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
• Provision of market value (USD Billion) data for each segment and sub-segment
• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
• Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
• The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
• Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
• Provides insight into the market through Value Chain
• Market dynamics scenario, along with growth opportunities of the market in the years to come
• 6-month post-sales analyst support

Customization of the Report

In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.

Chapter Outline

Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.

Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Nonalcoholic Steatohepatitis (NASH) Market and its likely evolution in the short to mid-term, and long term.

Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.

Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.

Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.

Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.

Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.

Chapter 12 is the main points and conclusions of the report.

Contents

1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE

1.1 Market Definition and Statistical Scope of Nonalcoholic Steatohepatitis (NASH)
1.2 Key Market Segments
  1.2.1 Nonalcoholic Steatohepatitis (NASH) Segment by Type
  1.2.2 Nonalcoholic Steatohepatitis (NASH) Segment by Application
1.3 Methodology & Sources of Information
  1.3.1 Research Methodology
  1.3.2 Research Process
  1.3.3 Market Breakdown and Data Triangulation
  1.3.4 Base Year
  1.3.5 Report Assumptions & Caveats

2 GLOBAL NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET OVERVIEW

2.1 Global Market Overview
  2.1.1 Global Nonalcoholic Steatohepatitis (NASH) Market Size (M USD) Estimates and Forecasts (2020-2033)
  2.1.2 Global Nonalcoholic Steatohepatitis (NASH) Sales Estimates and Forecasts (2020-2033)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region

3 GLOBAL NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET COMPETITIVE LANDSCAPE

3.1 Company Assessment Quadrant
3.2 Global Nonalcoholic Steatohepatitis (NASH) Product Life Cycle
3.3 Global Nonalcoholic Steatohepatitis (NASH) Sales by Manufacturers (2020-2025)
3.4 Global Nonalcoholic Steatohepatitis (NASH) Revenue Market Share by Manufacturers (2020-2025)
3.5 Nonalcoholic Steatohepatitis (NASH) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Nonalcoholic Steatohepatitis (NASH) Average Price by Manufacturers (2020-2025)
3.7 Manufacturers Nonalcoholic Steatohepatitis (NASH) Manufacturing Sites, Area Served, Product Type
3.8 Nonalcoholic Steatohepatitis (NASH) Market Competitive Situation and Trends
  3.8.1 Nonalcoholic Steatohepatitis (NASH) Market Concentration Rate
  3.8.2 Global 5 and 10 Largest Nonalcoholic Steatohepatitis (NASH) Players Market Share by Revenue
  3.8.3 Mergers & Acquisitions, Expansion

4 NONALCOHOLIC STEATOHEPATITIS (NASH) INDUSTRY CHAIN ANALYSIS

4.1 Nonalcoholic Steatohepatitis (NASH) Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis

5 THE DEVELOPMENT AND DYNAMICS OF NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET

5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Industry News
  5.4.1 New Product Developments
  5.4.2 Mergers & Acquisitions
  5.4.3 Expansions
  5.4.4 Collaboration/Supply Contracts
5.5 PEST Analysis
  5.5.1 Industry Policies Analysis
  5.5.2 Economic Environment Analysis
  5.5.3 Social Environment Analysis
  5.5.4 Technological Environment Analysis
5.6 Global Nonalcoholic Steatohepatitis (NASH) Market Porter's Five Forces Analysis
  5.6.1 Global Trade Frictions
  5.6.2 Global Trade Frictions and Their Impacts to Nonalcoholic Steatohepatitis (NASH) Market
5.7 ESG Ratings of Leading Companies

6 GLOBAL NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET BY REGION

6.1 Global Nonalcoholic Steatohepatitis (NASH) Market Size by Region
  6.1.1 Global Nonalcoholic Steatohepatitis (NASH) Market Size by Region
  6.1.2 Global Nonalcoholic Steatohepatitis (NASH) Market Size Market Share by Region
6.2 Global Nonalcoholic Steatohepatitis (NASH) Sales by Region
  6.2.1 Global Nonalcoholic Steatohepatitis (NASH) Sales by Region
  6.2.2 Global Nonalcoholic Steatohepatitis (NASH) Sales Market Share by Region

7 NORTH AMERICA MARKET OVERVIEW

7.1 North America Nonalcoholic Steatohepatitis (NASH) Market Size by Country
  7.1.1 USA Market Overview
  7.1.2 Canada Market Overview
  7.1.3 Mexico Market Overview
7.2 North America Nonalcoholic Steatohepatitis (NASH) Market Size by Type
7.3 North America Nonalcoholic Steatohepatitis (NASH) Market Size by Application

8 EUROPE MARKET OVERVIEW

8.1 Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Country
  8.1.1 Germany Market Overview
  8.1.2 France Market Overview
  8.1.3 U.K. Market Overview
  8.1.4 Italy Market Overview
  8.1.5 Spain Market Overview
8.2 Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Type
8.3 Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Application

9 ASIA-PACIFIC MARKET OVERVIEW

9.1 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size by Country
  9.1.1 China Market Overview
  9.1.2 Japan Market Overview
  9.1.3 South Korea Market Overview
  9.1.4 India Market Overview
  9.1.5 Southeast Asia Market Overview
9.2 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size by Type
9.3 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size by Application

10 SOUTH AMERICA MARKET OVERVIEW

10.1 South America Nonalcoholic Steatohepatitis (NASH) Market Size by Country
  10.1.1 Brazil Market Overview
  10.1.2 Argentina Market Overview
  10.1.3 Columbia Market Overview
10.2 South America Nonalcoholic Steatohepatitis (NASH) Market Size by Type
10.3 South America Nonalcoholic Steatohepatitis (NASH) Market Size by Application

11 MIDDLE EAST AND AFRICA MARKET OVERVIEW

11.1 Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Country
  11.1.1 Saudi Arabia Market Overview
  11.1.2 UAE Market Overview
  11.1.3 Egypt Market Overview
  11.1.4 Nigeria Market Overview
  11.1.5 South Africa Market Overview
11.2 Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Type
11.3 Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Application

12 NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET PRODUCTION BY REGION

12.1 Global Production of Nonalcoholic Steatohepatitis (NASH) by Region(2020-2025)
12.2 Global Nonalcoholic Steatohepatitis (NASH) Revenue Market Share by Region (2020-2025)
12.3 Global Nonalcoholic Steatohepatitis (NASH) Production, Revenue, Price and Gross Margin (2020-2025)
12.4 North America Nonalcoholic Steatohepatitis (NASH) Production
  12.4.1 North America Nonalcoholic Steatohepatitis (NASH) Production Growth Rate (2020-2025)
  12.4.2 North America Nonalcoholic Steatohepatitis (NASH) Production, Revenue, Price and Gross Margin (2020-2025)
12.5 Europe Nonalcoholic Steatohepatitis (NASH) Production
  12.5.1 Europe Nonalcoholic Steatohepatitis (NASH) Production Growth Rate (2020-2025)
  12.5.2 Europe Nonalcoholic Steatohepatitis (NASH) Production, Revenue, Price and Gross Margin (2020-2025)
12.6 Japan Nonalcoholic Steatohepatitis (NASH) Production (2020-2025)
  12.6.1 Japan Nonalcoholic Steatohepatitis (NASH) Production Growth Rate (2020-2025)
  12.6.2 Japan Nonalcoholic Steatohepatitis (NASH) Production, Revenue, Price and Gross Margin (2020-2025)
12.7 China Nonalcoholic Steatohepatitis (NASH) Production (2020-2025)
  12.7.1 China Nonalcoholic Steatohepatitis (NASH) Production Growth Rate (2020-2025)
  12.7.2 China Nonalcoholic Steatohepatitis (NASH) Production, Revenue, Price and Gross Margin (2020-2025)

13 NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET SEGMENTATION BY TYPE

13.1 Evaluation Matrix of Segment Market Development Potential (Type)
13.2 Global Nonalcoholic Steatohepatitis (NASH) Sales Market Share by Type (2020-2033)
13.3 Global Nonalcoholic Steatohepatitis (NASH) Market Size Market Share by Type (2020-2033)
13.4 Global Nonalcoholic Steatohepatitis (NASH) Price by Type (2020-2033)

14 NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET SEGMENTATION BY APPLICATION

14.1 Evaluation Matrix of Segment Market Development Potential (Application)
14.2 Global Nonalcoholic Steatohepatitis (NASH) Market Sales by Application (2020-2033)
14.3 Global Nonalcoholic Steatohepatitis (NASH) Market Size (M USD) by Application (2020-2033)
14.4 Global Nonalcoholic Steatohepatitis (NASH) Sales Growth Rate by Application (2020-2033)

15 KEY COMPANIES PROFILE

15.1 AstraZeneca
  15.1.1 AstraZeneca Basic Information
  15.1.2 AstraZeneca Nonalcoholic Steatohepatitis (NASH) Product Overview
  15.1.3 AstraZeneca Nonalcoholic Steatohepatitis (NASH) Product Market Performance
  15.1.4 AstraZeneca Business Overview
  15.1.5 AstraZeneca SWOT Analysis
  15.1.6 AstraZeneca Recent Developments
15.2 Arena Pharmaceuticals
  15.2.1 Arena Pharmaceuticals Basic Information
  15.2.2 Arena Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product Overview
  15.2.3 Arena Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product Market Performance
  15.2.4 Arena Pharmaceuticals Business Overview
  15.2.5 Arena Pharmaceuticals SWOT Analysis
  15.2.6 Arena Pharmaceuticals Recent Developments
15.3 GSK
  15.3.1 GSK Basic Information
  15.3.2 GSK Nonalcoholic Steatohepatitis (NASH) Product Overview
  15.3.3 GSK Nonalcoholic Steatohepatitis (NASH) Product Market Performance
  15.3.4 GSK Business Overview
  15.3.5 GSK SWOT Analysis
  15.3.6 GSK Recent Developments
15.4 Novo Nordisk
  15.4.1 Novo Nordisk Basic Information
  15.4.2 Novo Nordisk Nonalcoholic Steatohepatitis (NASH) Product Overview
  15.4.3 Novo Nordisk Nonalcoholic Steatohepatitis (NASH) Product Market Performance
  15.4.4 Novo Nordisk Business Overview
  15.4.5 Novo Nordisk Recent Developments
15.5 Roche
  15.5.1 Roche Basic Information
  15.5.2 Roche Nonalcoholic Steatohepatitis (NASH) Product Overview
  15.5.3 Roche Nonalcoholic Steatohepatitis (NASH) Product Market Performance
  15.5.4 Roche Business Overview
  15.5.5 Roche Recent Developments
15.6 Vivus
  15.6.1 Vivus Basic Information
  15.6.2 Vivus Nonalcoholic Steatohepatitis (NASH) Product Overview
  15.6.3 Vivus Nonalcoholic Steatohepatitis (NASH) Product Market Performance
  15.6.4 Vivus Business Overview
  15.6.5 Vivus Recent Developments
15.7 Arisaph Pharmaceuticals
  15.7.1 Arisaph Pharmaceuticals Basic Information
  15.7.2 Arisaph Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product Overview
  15.7.3 Arisaph Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product Market Performance
  15.7.4 Arisaph Pharmaceuticals Business Overview
  15.7.5 Arisaph Pharmaceuticals Recent Developments
15.8 Cempra Pharmaceuticals
  15.8.1 Cempra Pharmaceuticals Basic Information
  15.8.2 Cempra Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product Overview
  15.8.3 Cempra Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product Market Performance
  15.8.4 Cempra Pharmaceuticals Business Overview
  15.8.5 Cempra Pharmaceuticals Recent Developments
15.9 Galectin Therapeutics
  15.9.1 Galectin Therapeutics Basic Information
  15.9.2 Galectin Therapeutics Nonalcoholic Steatohepatitis (NASH) Product Overview
  15.9.3 Galectin Therapeutics Nonalcoholic Steatohepatitis (NASH) Product Market Performance
  15.9.4 Galectin Therapeutics Business Overview
  15.9.5 Galectin Therapeutics Recent Developments
15.10 Galmed Pharmaceuticals
  15.10.1 Galmed Pharmaceuticals Basic Information
  15.10.2 Galmed Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product Overview
  15.10.3 Galmed Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product Market Performance
  15.10.4 Galmed Pharmaceuticals Business Overview
  15.10.5 Galmed Pharmaceuticals Recent Developments
15.11 Genfit
  15.11.1 Genfit Basic Information
  15.11.2 Genfit Nonalcoholic Steatohepatitis (NASH) Product Overview
  15.11.3 Genfit Nonalcoholic Steatohepatitis (NASH) Product Market Performance
  15.11.4 Genfit Business Overview
  15.11.5 Genfit Recent Developments
15.12 Gilead
  15.12.1 Gilead Basic Information
  15.12.2 Gilead Nonalcoholic Steatohepatitis (NASH) Product Overview
  15.12.3 Gilead Nonalcoholic Steatohepatitis (NASH) Product Market Performance
  15.12.4 Gilead Business Overview
  15.12.5 Gilead Recent Developments

16 CONCLUSION AND KEY FINDINGS
List of Tables
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Global Nonalcoholic Steatohepatitis (NASH) Market Size by Type (M USD)
Table 4. Global Nonalcoholic Steatohepatitis (NASH) Market Size by Application (M USD)
Table 5. Nonalcoholic Steatohepatitis (NASH) Market Size Comparison by Region (M USD)
Table 6. Global Nonalcoholic Steatohepatitis (NASH) Sales (K Units) by Manufacturers (2020-2025)
Table 7. Global Nonalcoholic Steatohepatitis (NASH) Sales Market Share by Manufacturers (2020-2025)
Table 8. Global Nonalcoholic Steatohepatitis (NASH) Revenue (M USD) by Manufacturers (2020-2025)
Table 9. Global Nonalcoholic Steatohepatitis (NASH) Revenue Share by Manufacturers (2020-2025)
Table 10. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Nonalcoholic Steatohepatitis (NASH) as of 2024)
Table 11. Global Market Nonalcoholic Steatohepatitis (NASH) Average Price (USD/Unit) of Key Manufacturers (2020-2025)
Table 12. Manufacturers Nonalcoholic Steatohepatitis (NASH) Manufacturing Sites and Area Served
Table 13. Manufacturers Nonalcoholic Steatohepatitis (NASH) Product Type
Table 14. Global Nonalcoholic Steatohepatitis (NASH) Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Nonalcoholic Steatohepatitis (NASH) Market Challenges
Table 22. Goldman Sachs' forecast real GDP growth rate for 2024-2026
Table 23. S&P Global ' Forecast Real GDP Growth Rate For 2024-2027
Table 24. World Bank ' Forecast Real GDP Growth Rate For 2024-2026
Table 25. Nonalcoholic Steatohepatitis (NASH) Market Size Comparison by Region (M USD)
Table 26. Global Nonalcoholic Steatohepatitis (NASH) Market Size by Region (2020-2033) & (M USD)
Table 27. Global Nonalcoholic Steatohepatitis (NASH) Market Size Market Share by Region (2020-2033)
Table 28. Global Nonalcoholic Steatohepatitis (NASH) Sales by Region (2020-2033) & (K Units)
Table 29. Global Nonalcoholic Steatohepatitis (NASH) Sales Market Share by Region (2020-2033)
Table 30. North America Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2020-2033) & (M USD)
Table 31. North America Nonalcoholic Steatohepatitis (NASH) Sales by Country (2020-2033) & (K Units)
Table 32. North America Nonalcoholic Steatohepatitis (NASH) Sales by Type (K Units)
Table 33. North America Nonalcoholic Steatohepatitis (NASH) Market Size by Type (M USD)
Table 34. North America Nonalcoholic Steatohepatitis (NASH) Sales (K Units) by Type (2020-2033)
Table 35. North America Nonalcoholic Steatohepatitis (NASH) Market Size (M USD) by Type (2020-2033)
Table 36. North America Nonalcoholic Steatohepatitis (NASH) Sales by Application (K Units)
Table 37. North America Nonalcoholic Steatohepatitis (NASH) Market Size by Application (M USD)
Table 38. North America Nonalcoholic Steatohepatitis (NASH) Sales (K Units) by Application (2020-2033)
Table 39. North America Nonalcoholic Steatohepatitis (NASH) Market Size (M USD) by Application (2020-2033)
Table 40. Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2020-2033) & (M USD)
Table 41. Europe Nonalcoholic Steatohepatitis (NASH) Sales by Country (2020-2033) & (K Units)
Table 42. Europe Nonalcoholic Steatohepatitis (NASH) Sales by Type (K Units)
Table 43. Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Type (M USD)
Table 44. Europe Nonalcoholic Steatohepatitis (NASH) Sales (K Units) by Type (2020-2033)
Table 45. Europe Nonalcoholic Steatohepatitis (NASH) Market Size (M USD) by Type (2020-2033)
Table 46. Europe Nonalcoholic Steatohepatitis (NASH) Sales by Application (K Units)
Table 47. Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Application (M USD)
Table 48. Europe Nonalcoholic Steatohepatitis (NASH) Sales (K Units) by Application (2020-2033)
Table 49. Europe Nonalcoholic Steatohepatitis (NASH) Market Size (M USD) by Application (2020-2033)
Table 50. Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2020-2025) & (M USD)
Table 51. Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Sales by Country (2020-2025) & (K Units)
Table 52. Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Sales by Type (K Units)
Table 53. Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size by Type (M USD)
Table 54. Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Sales (K Units) by Type (2020-2033)
Table 55. Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size (M USD) by Type (2020-2025)
Table 56. Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Sales by Application (K Units)
Table 57. Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size by Application (M USD)
Table 58. Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Sales (K Units) by Application (2020-2033)
Table 59. Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size (M USD) by Application (2020-2025)
Table 60. South America Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2020-2033) & (M USD)
Table 61. South America Nonalcoholic Steatohepatitis (NASH) Sales by Country (2020-2033) & (K Units)
Table 62. South America Nonalcoholic Steatohepatitis (NASH) Sales by Type (K Units)
Table 63. South America Nonalcoholic Steatohepatitis (NASH) Market Size by Type (M USD)
Table 64. South America Nonalcoholic Steatohepatitis (NASH) Sales (K Units) by Type (2020-2033)
Table 65. South America Nonalcoholic Steatohepatitis (NASH) Market Size (M USD) by Type (2020-2033)
Table 66. South America Nonalcoholic Steatohepatitis (NASH) Sales by Application (K Units)
Table 67. South America Nonalcoholic Steatohepatitis (NASH) Market Size by Application (M USD)
Table 68. South America Nonalcoholic Steatohepatitis (NASH) Sales (K Units) by Application (2020-2033)
Table 69. South America Nonalcoholic Steatohepatitis (NASH) Market Size (M USD) by Application (2020-2033)
Table 70. Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Country (2020-2033) & (M USD)
Table 71. Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Sales by Country (2020-2033) & (K Units)
Table 72. Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Sales by Type (K Units)
Table 73. Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Type (M USD)
Table 74. Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Sales (K Units) by Type (2020-2033)
Table 75. Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Market Size (M USD) by Type (2020-2033)
Table 76. Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Sales by Application (K Units)
Table 77. Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Application (M USD)
Table 78. Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Sales (K Units) by Application (2020-2033)
Table 79. Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Market Size (M USD) by Application (2020-2033)
Table 80. Global Nonalcoholic Steatohepatitis (NASH) Production (K Units) by Region(2020-2025)
Table 81. Global Nonalcoholic Steatohepatitis (NASH) Revenue (US$ Million) by Region (2020-2025)
Table 82. Global Nonalcoholic Steatohepatitis (NASH) Revenue Market Share by Region (2020-2025)
Table 83. Global Nonalcoholic Steatohepatitis (NASH) Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 84. North America Nonalcoholic Steatohepatitis (NASH) Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 85. Europe Nonalcoholic Steatohepatitis (NASH) Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 86. Japan Nonalcoholic Steatohepatitis (NASH) Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 87. China Nonalcoholic Steatohepatitis (NASH) Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 88. Global Nonalcoholic Steatohepatitis (NASH) Sales by Type (K Units)
Table 89. Global Nonalcoholic Steatohepatitis (NASH) Market Size by Type (M USD)
Table 90. Global Nonalcoholic Steatohepatitis (NASH) Sales (K Units) by Type (2020-2033)
Table 91. Global Nonalcoholic Steatohepatitis (NASH) Sales Market Share by Type (2020-2033)
Table 92. Global Nonalcoholic Steatohepatitis (NASH) Market Size (M USD) by Type (2020-2033)
Table 93. Global Nonalcoholic Steatohepatitis (NASH) Market Size Share by Type (2020-2033)
Table 94. Global Nonalcoholic Steatohepatitis (NASH) Sales (K Units) by Application
Table 95. Global Nonalcoholic Steatohepatitis (NASH) Market Size by Application(M USD)
Table 96. Global Nonalcoholic Steatohepatitis (NASH) Sales by Application (2020-2033) & (K Units)
Table 97. Global Nonalcoholic Steatohepatitis (NASH) Sales Market Share by Application (2020-2033)
Table 98. Global Nonalcoholic Steatohepatitis (NASH) Market Size by Application (2020-2033) & (M USD)
Table 99. Global Nonalcoholic Steatohepatitis (NASH) Market Share by Application (2020-2033)
Table 100. Global Nonalcoholic Steatohepatitis (NASH) Sales Growth Rate by Application (2020-2033)
Table 101. AstraZeneca Basic Information
Table 102. AstraZeneca Nonalcoholic Steatohepatitis (NASH) Product Overview
Table 103. AstraZeneca Nonalcoholic Steatohepatitis (NASH) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 104. AstraZeneca Business Overview
Table 105. AstraZeneca SWOT Analysis
Table 106. AstraZeneca Recent Developments
Table 107. Arena Pharmaceuticals Basic Information
Table 108. Arena Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product Overview
Table 109. Arena Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 110. Arena Pharmaceuticals Business Overview
Table 111. Arena Pharmaceuticals SWOT Analysis
Table 112. Arena Pharmaceuticals Recent Developments
Table 113. GSK Basic Information
Table 114. GSK Nonalcoholic Steatohepatitis (NASH) Product Overview
Table 115. GSK Nonalcoholic Steatohepatitis (NASH) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 116. GSK Business Overview
Table 117. GSK SWOT Analysis
Table 118. GSK Recent Developments
Table 119. Novo Nordisk Basic Information
Table 120. Novo Nordisk Nonalcoholic Steatohepatitis (NASH) Product Overview
Table 121. Novo Nordisk Nonalcoholic Steatohepatitis (NASH) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 122. Novo Nordisk Business Overview
Table 123. Novo Nordisk Recent Developments
Table 124. Roche Basic Information
Table 125. Roche Nonalcoholic Steatohepatitis (NASH) Product Overview
Table 126. Roche Nonalcoholic Steatohepatitis (NASH) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 127. Roche Business Overview
Table 128. Roche Recent Developments
Table 129. Vivus Basic Information
Table 130. Vivus Nonalcoholic Steatohepatitis (NASH) Product Overview
Table 131. Vivus Nonalcoholic Steatohepatitis (NASH) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 132. Vivus Business Overview
Table 133. Vivus Recent Developments
Table 134. Arisaph Pharmaceuticals Basic Information
Table 135. Arisaph Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product Overview
Table 136. Arisaph Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 137. Arisaph Pharmaceuticals Business Overview
Table 138. Arisaph Pharmaceuticals Recent Developments
Table 139. Cempra Pharmaceuticals Basic Information
Table 140. Cempra Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product Overview
Table 141. Cempra Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 142. Cempra Pharmaceuticals Business Overview
Table 143. Cempra Pharmaceuticals Recent Developments
Table 144. Galectin Therapeutics Basic Information
Table 145. Galectin Therapeutics Nonalcoholic Steatohepatitis (NASH) Product Overview
Table 146. Galectin Therapeutics Nonalcoholic Steatohepatitis (NASH) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 147. Galectin Therapeutics Business Overview
Table 148. Galectin Therapeutics Recent Developments
Table 149. Galmed Pharmaceuticals Basic Information
Table 150. Galmed Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product Overview
Table 151. Galmed Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 152. Galmed Pharmaceuticals Business Overview
Table 153. Galmed Pharmaceuticals Recent Developments
Table 154. Genfit Basic Information
Table 155. Genfit Nonalcoholic Steatohepatitis (NASH) Product Overview
Table 156. Genfit Nonalcoholic Steatohepatitis (NASH) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 157. Genfit Business Overview
Table 158. Genfit Recent Developments
Table 159. Gilead Basic Information
Table 160. Gilead Nonalcoholic Steatohepatitis (NASH) Product Overview
Table 161. Gilead Nonalcoholic Steatohepatitis (NASH) Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2020-2025)
Table 162. Gilead Business Overview
Table 163. Gilead Recent Developments
List of Figures
Figure 1. Product Picture of Nonalcoholic Steatohepatitis (NASH)
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Nonalcoholic Steatohepatitis (NASH) Market Size (M USD), 2024-2033
Figure 5. Global Nonalcoholic Steatohepatitis (NASH) Market Size (M USD) (2020-2033)
Figure 6. Global Nonalcoholic Steatohepatitis (NASH) Sales (K Units) & (2020-2033)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Nonalcoholic Steatohepatitis (NASH) Market Size by Country (M USD)
Figure 11. Company Assessment Quadrant
Figure 12. Global Nonalcoholic Steatohepatitis (NASH) Product Life Cycle
Figure 13. Nonalcoholic Steatohepatitis (NASH) Sales Share by Manufacturers in 2024
Figure 14. Global Nonalcoholic Steatohepatitis (NASH) Revenue Share by Manufacturers in 2024
Figure 15. Nonalcoholic Steatohepatitis (NASH) Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2024
Figure 16. Global Market Nonalcoholic Steatohepatitis (NASH) Average Price (USD/Unit) of Key Manufacturers in 2024
Figure 17. The Global 5 and 10 Largest Players: Market Share by Nonalcoholic Steatohepatitis (NASH) Revenue in 2024
Figure 18. Industry Chain Map of Nonalcoholic Steatohepatitis (NASH)
Figure 19. Global Nonalcoholic Steatohepatitis (NASH) Market PEST Analysis
Figure 20. Global Nonalcoholic Steatohepatitis (NASH) Market Porter's Five Forces Analysis
Figure 21. Global Merchandise Trade as a Percentage Of GDP
Figure 22. US - lmports of Goods by Country
Figure 23. China Exports by Country
Figure 24. ESG Rating Distribution of The Leading Company Compared With Its Peers
Figure 25. Evaluation Matrix of Regional Market Development Potential
Figure 26. Global Nonalcoholic Steatohepatitis (NASH) Market Size by Region
Figure 27. Global Nonalcoholic Steatohepatitis (NASH) Market Size Market Share by Region (2020-2033)
Figure 28. Global Nonalcoholic Steatohepatitis (NASH) Sales Market Share by Region (2020-2033)
Figure 29. North American Market Snapshot
Figure 30. North America Nonalcoholic Steatohepatitis (NASH) Sales and Growth Rate (2020-2033) & (K Units)
Figure 31. North America Nonalcoholic Steatohepatitis (NASH) Market Size and Growth Rate (2020-2033) & (M USD)
Figure 32. North America Nonalcoholic Steatohepatitis (NASH) Market Size (M USD) by Country
Figure 33. USA Nonalcoholic Steatohepatitis (NASH) Sales and Growth Rate (2020-2033) & (K Units)
Figure 34. USA Nonalcoholic Steatohepatitis (NASH) Market Size and Growth Rate (2020-2033) & (M USD)
Figure 35. Canada Nonalcoholic Steatohepatitis (NASH) Sales (K Units) and Growth Rate (2020-2033)
Figure 36. Canada Nonalcoholic Steatohepatitis (NASH) Market Size (M USD) and Growth Rate (2020-2033)
Figure 37. Mexico Nonalcoholic Steatohepatitis (NASH) Sales (Units) and Growth Rate (2020-2033)
Figure 38. Mexico Nonalcoholic Steatohepatitis (NASH) Market Size (M USD) and Growth Rate (2020-2033)
Figure 39. North America Nonalcoholic Steatohepatitis (NASH) Market Size (M USD)by Type
Figure 40. North America Nonalcoholic Steatohepatitis (NASH) Market Size (M USD) by Application
Figure 41. Europe Market Snapshot
Figure 42. Europe Nonalcoholic Steatohepatitis (NASH) Sales and Growth Rate (2020-2033) & (K Units)
Figure 43. Europe Nonalcoholic Steatohepatitis (NASH) Market Size and Growth Rate (2020-2033) & (M USD)
Figure 44. Europe Nonalcoholic Steatohepatitis (NASH) Market Size (M USD) by Country
Figure 45. Germany Nonalcoholic Steatohepatitis (NASH) Sales and Growth Rate (2020-2033) & (K Units)
Figure 46. Germany Nonalcoholic Steatohepatitis (NASH) Market Size and Growth Rate (2020-2033) & (M USD)
Figure 47. France Nonalcoholic Steatohepatitis (NASH) Sales and Growth Rate (2020-2033) & (K Units)
Figure 48. France Nonalcoholic Steatohepatitis (NASH) Market Size and Growth Rate (2020-2033) & (M USD)
Figure 49. U.K. Nonalcoholic Steatohepatitis (NASH) Sales and Growth Rate (2020-2033) & (K Units)
Figure 50. U.K. Nonalcoholic Steatohepatitis (NASH) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 51. Italy Nonalcoholic Steatohepatitis (NASH) Sales and Growth Rate (2020-2033) & (K Units)
Figure 52. Italy Nonalcoholic Steatohepatitis (NASH) Market Size and Growth Rate (2020-2033) & (M USD)
Figure 53. Spain Nonalcoholic Steatohepatitis (NASH) Sales and Growth Rate (2020-2033) & (K Units)
Figure 54. Spain Nonalcoholic Steatohepatitis (NASH) Market Size and Growth Rate (2020-2033) & (M USD)
Figure 55. Europe Nonalcoholic Steatohepatitis (NASH) Market Size (M USD) by Type
Figure 56. Europe Nonalcoholic Steatohepatitis (NASH) Market Size (M USD) by Application
Figure 57. Asia-Pacific Market Snapshot
Figure 58. Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Sales and Growth Rate (2020-2033) & (K Units)
Figure 59. Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 60. Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size (M USD) by Country
Figure 61. China Nonalcoholic Steatohepatitis (NASH) Sales and Growth Rate (2020-2025) & (K Units)
Figure 62. China Nonalcoholic Steatohepatitis (NASH) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 63. Japan Nonalcoholic Steatohepatitis (NASH) Sales and Growth Rate (2020-2025) & (K Units)
Figure 64. Japan Nonalcoholic Steatohepatitis (NASH) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 65. South Korea Nonalcoholic Steatohepatitis (NASH) Sales and Growth Rate (2020-2025) & (K Units)
Figure 66. South Korea Nonalcoholic Steatohepatitis (NASH) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 67. India Nonalcoholic Steatohepatitis (NASH) Sales and Growth Rate (2020-2025) & (K Units)
Figure 68. India Nonalcoholic Steatohepatitis (NASH) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 69. Southeast Asia Nonalcoholic Steatohepatitis (NASH) Sales and Growth Rate (2020-2025) & (K Units)
Figure 70. Southeast Asia Nonalcoholic Steatohepatitis (NASH) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 71. Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size (M USD) by Type
Figure 72. Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size (M USD) by Application
Figure 73. South America Market Snapshot
Figure 74. South America Nonalcoholic Steatohepatitis (NASH) Sales and Growth Rate (2020-2033) & (K Units)
Figure 75. South America Nonalcoholic Steatohepatitis (NASH) Market Size and Growth Rate (2020-2033) & (M USD)
Figure 76. South America Nonalcoholic Steatohepatitis (NASH) Market Size (M USD) by Country
Figure 77. Brazil Nonalcoholic Steatohepatitis (NASH) Sales and Growth Rate (2020-2033) & (K Units)
Figure 78. Brazil Nonalcoholic Steatohepatitis (NASH) Market Size and Growth Rate (2020-2033) & (M USD)
Figure 79. Argentina Nonalcoholic Steatohepatitis (NASH) Sales and Growth Rate (2020-2033) & (K Units)
Figure 80. Argentina Nonalcoholic Steatohepatitis (NASH) Market Size and Growth Rate (2020-2033) & (M USD)
Figure 81. Columbia Nonalcoholic Steatohepatitis (NASH) Sales and Growth Rate (2020-2033) & (K Units)
Figure 82. Columbia Nonalcoholic Steatohepatitis (NASH) Market Size and Growth Rate (2020-2033) & (M USD)
Figure 83. South America Nonalcoholic Steatohepatitis (NASH) Market Size (M USD) by Type
Figure 84. South America Nonalcoholic Steatohepatitis (NASH) Market Size (M USD) by Application
Figure 85. Middle East and Africa Market Snapshot
Figure 86. Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Sales and Growth Rate (2020-2033) & (K Units)
Figure 87. Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Market Size and Growth Rate (2020-2033) & (M USD)
Figure 88. Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Market Size (M USD) by Country
Figure 89. Saudi Arabia Nonalcoholic Steatohepatitis (NASH) Sales and Growth Rate (2020-2033) & (K Units)
Figure 90. Saudi Arabia Nonalcoholic Steatohepatitis (NASH) Market Size and Growth Rate (2020-2033) & (M USD)
Figure 91. UAE Nonalcoholic Steatohepatitis (NASH) Sales and Growth Rate (2020-2033) & (K Units)
Figure 92. UAE Nonalcoholic Steatohepatitis (NASH) Market Size and Growth Rate (2020-2033) & (M USD)
Figure 93. Egypt Nonalcoholic Steatohepatitis (NASH) Sales and Growth Rate (2020-2033) & (K Units)
Figure 94. Egypt Nonalcoholic Steatohepatitis (NASH) Market Size and Growth Rate (2020-2033) & (M USD)
Figure 95. Nigeria Nonalcoholic Steatohepatitis (NASH) Sales and Growth Rate (2020-2033) & (K Units)
Figure 96. Nigeria Nonalcoholic Steatohepatitis (NASH) Market Size and Growth Rate (2020-2033) & (M USD)
Figure 97. South Africa Nonalcoholic Steatohepatitis (NASH) Sales and Growth Rate (2020-2033) & (K Units)
Figure 98. South Africa Nonalcoholic Steatohepatitis (NASH) Market Size and Growth Rate (2020-2033) & (M USD)
Figure 99. Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Market Size (M USD) by Type
Figure 100. Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Market Size (M USD) by Application
Figure 101. Global Nonalcoholic Steatohepatitis (NASH) Production Market Share by Region (2020-2025)
Figure 102. North America Nonalcoholic Steatohepatitis (NASH) Production (K Units) Growth Rate (2020-2025)
Figure 103. Europe Nonalcoholic Steatohepatitis (NASH) Production (K Units) Growth Rate (2020-2025)
Figure 104. Japan Nonalcoholic Steatohepatitis (NASH) Production (K Units) Growth Rate (2020-2025)
Figure 105. China Nonalcoholic Steatohepatitis (NASH) Production (K Units) Growth Rate (2020-2025)
Figure 106. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 107. Global Nonalcoholic Steatohepatitis (NASH) Market Size by Type (M USD)
Figure 108. Sales Market Share of Nonalcoholic Steatohepatitis (NASH) by Type (2020-2033)
Figure 109. Sales Market Share of Nonalcoholic Steatohepatitis (NASH) by Type in 2024
Figure 110. Market Size Share of Nonalcoholic Steatohepatitis (NASH) by Type (2020-2033)
Figure 111. Market Size Share of Nonalcoholic Steatohepatitis (NASH) by Type in 2024
Figure 112. Global Nonalcoholic Steatohepatitis (NASH) Price (USD/Unit) by Type (2020-2033)
Figure 113. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 114. Global Nonalcoholic Steatohepatitis (NASH) Market Size by Application(M USD)
Figure 115. Global Nonalcoholic Steatohepatitis (NASH) Market Share by Application
Figure 116. Global Nonalcoholic Steatohepatitis (NASH) Sales Market Share by Application (2020-2033)
Figure 117. Global Nonalcoholic Steatohepatitis (NASH) Sales Market Share by Application in 2024
Figure 118. Global Nonalcoholic Steatohepatitis (NASH) Market Share by Application (2020-2033)
Figure 119. Global Nonalcoholic Steatohepatitis (NASH) Market Share by Application in 2024
Figure 120. Global Nonalcoholic Steatohepatitis (NASH) Sales Growth Rate by Application (2020-2033)